Modified Amino Acid Levacetylleucine Eases Symptoms in Rare Neurological Disorder
A phase III trial shows levacetylleucine meaningfully improves neurologic function in ataxia-telangiectasia patients with a strong safety profile.
Summary
Ataxia-telangiectasia is a rare inherited disease that causes progressive neurological decline, immune dysfunction, and premature death. A phase III crossover trial of 73 adults and children found that oral levacetylleucine — a modified amino acid already approved for Niemann-Pick disease — improved ataxia scores by nearly 2 points compared to placebo over 12 weeks. A 1-point change is considered clinically meaningful. The drug also improved quality of life and showed a favorable safety profile, with only minor transient side effects. Published in Lancet Neurology, this is the first pharmacological evidence that a downstream intervention can produce meaningful symptomatic improvement in this devastating disorder, offering hope where treatment options have historically been limited to supportive care.
Detailed Summary
Ataxia-telangiectasia (A-T) is a rare genetic disorder caused by mutations in the ATM gene, which governs DNA damage response. The condition leads to progressive cerebellar degeneration, immune deficiency, cancer susceptibility, and significantly reduced lifespan — typically beginning in early childhood. Until now, treatment has been almost entirely supportive, with no proven pharmacological options to slow or reverse neurological decline.
A phase III randomized crossover trial published in Lancet Neurology tested levacetylleucine, a modified amino acid, in 73 adults and children with A-T. The primary endpoint was the change in Scale for the Assessment and Rating of Ataxia (SARA) scores after 12 weeks. Patients on levacetylleucine improved by 1.92 points versus just 0.14 points on placebo — a statistically significant and clinically meaningful difference, since even a 1-point change is considered relevant by clinical standards.
Quality of life measures also improved with levacetylleucine compared to placebo. Adverse events were minimal: only two patients experienced three treatment-emergent events related to the drug (diarrhea, eczema, and insomnia), all of which were transient. There were no serious adverse events, treatment-related discontinuations, or deaths.
Levacetylleucine (brand name Aqneursa) was approved in 2024 for neurologic manifestations of Niemann-Pick disease type C. This trial represents its first major evidence base for A-T. An ongoing open-label extension phase will investigate whether the drug has long-term neuroprotective or disease-modifying effects beyond symptomatic relief.
For the broader longevity and neurological health community, this finding is significant: it demonstrates that a relatively simple oral compound can intervene meaningfully in a condition driven by impaired DNA damage response — a pathway also central to normal aging biology. While A-T is rare, insights into ATM-pathway modulation may have wider implications for age-related neurodegeneration research.
Key Findings
- Levacetylleucine improved ataxia scores by 1.92 points vs 0.14 for placebo over 12 weeks in A-T patients.
- A 1-point SARA score change is clinically meaningful; the drug exceeded this threshold significantly.
- Only 3 minor, transient adverse events were linked to levacetylleucine; no serious events or deaths occurred.
- Drug is already FDA-approved for Niemann-Pick disease type C, supporting an established safety track record.
- Open-label extension will assess potential long-term neuroprotective and disease-modifying effects.
Methodology
This is a news report summarizing a phase III randomized crossover trial published in Lancet Neurology, a high-credibility peer-reviewed journal. The trial enrolled 73 adult and pediatric patients and used a validated ataxia rating scale as the primary endpoint. The crossover design strengthens internal validity by allowing each participant to serve as their own control.
Study Limitations
The 12-week trial duration limits conclusions about long-term efficacy or disease modification; extension data are still pending. The small sample size (73 patients) reflects the rarity of the condition and may limit statistical power for subgroup analyses. Levacetylleucine remains investigational for A-T specifically, and regulatory approval for this indication has not yet been granted.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: